Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

BACKGROUND: First-line maintenance erlotinib in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) has demonstrated significant overall survival and progression-free survival benefits compared with best supportive care plus placebo, irrespective of epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Walleser, Silke, Ray, Joshua, Bischoff, Helge, Vergnenègre, Alain, Rosery, Hubertus, Chouaid, Christos, Heigener, David, de Castro Carpeño, Javier, Tiseo, Marcello, Walzer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447427/
https://www.ncbi.nlm.nih.gov/pubmed/23028234
http://dx.doi.org/10.2147/CEOR.S31794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447427/
https://www.ncbi.nlm.nih.gov/pubmed/23028234
http://dx.doi.org/10.2147/CEOR.S31794

Ejemplares similares